Minimising critical organ irradiation in limited stage Hodgkin lymphoma: A dosimetric study of the benefit of involved node radiotherapy

Annals of Oncology

Volumn 23, Issue 5, 2012, Pages 1259-1266

  Campbell, B A ^a   Hornby, C ^a   Cunninghame, J ^a   Burns, M ^a   Macmanus, M ^a   Ryan, G ^a   Lau, E ^a,b   Seymour, J F ^a,b   Wirth, A ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Dosimetry; Hodgkin lymphoma; INRT; Involved node radiotherapy; Organs at risk; Toxicity

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; FEMALE; HODGKIN DISEASE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; LYMPH NODE IRRADIATION; ORGANS AT RISK; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTON THERAPY; RADIATION DOSE FRACTIONATION; RADIATION EXPOSURE; RADIATION RESPONSE; RISK ASSESSMENT; RISK FACTOR; VOLUMETRY;

ADULT; DIAPHRAGM; FEMALE; HODGKIN DISEASE; HUMANS; LYMPH NODES; LYMPHATIC IRRADIATION; LYMPHATIC METASTASIS; MIDDLE AGED; ORGAN SPARING TREATMENTS; ORGANS AT RISK; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RISK ASSESSMENT; YOUNG ADULT;

EID: 84860450201     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr439     Document Type: Article

References (28)

1. Herbst C, Rehan FA, Brillant C et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review. Haematologica 2010; 95: 494-500.
2. Campbell BA, Voss N, Pickles T et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size. J Clin Oncol 2008; 26: 5170-5174.
3. Dores GM, Metayer C, Curtis RE et al. Second malignant neoplasms among longterm survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 2002; 20: 3484-3494.
4. Girinsky T, van der Maazen R, Specht L et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006; 79: 270-277.
5. Hall EJ, Wuu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003; 56: 83-88.
6. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 2006; 65: 1-7.
7. Weber DC, Peguret N, Dipasquale G, Cozzi L. Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study. Int J Radiat Oncol Biol Phys 2009; 75: 1578-1586.
8. Girinsky T, Pichenot C, Beaudre A et al. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys 2006; 64: 218-226.
9. Study Protocols for Primary Treatment: HD10 Limited Stages, HD11-Intermediate Stages. Hodgkin Study Trial Coordination, German Hodgkin Study Group, Cologne, Germany: 1998.
10. Yahalom J, Mauch P. The involved field is back: issues in delineating the radiation field in Hodgkin's disease. Ann Oncol 2002; 13 (Suppl 1): 79-83.
11. Senan S, Piet A, Lagerwaard F. Involved-node radiotherapy to the mediastinum. Radiother Oncol 2007; 82: 108-109; author reply 109-110.
12. Penagaricano JA, Yan Y, Shi C et al. Dosimetric comparison of helical tomotherapy and Gamma Knife stereotactic radiosurgery for single brain metastasis. Radiat Oncol 2006; 1: 26.
13. SPSS for Windows 17.0SPSS for Windows 17.0. Chicago, IL: SPSS Inc. 2008.
14. Shahidi M, Kamangari N, Ashley S et al. Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease. Radiother Oncol 2006; 78: 1-5.
15. Eich HT, Muller RP, Engenhart-Cabillic R et al. Involved-node radiotherapy in early-stage Hodgkin's lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol 2008; 184: 406-410.
16. Aleman BM, van den Belt-Dusebout AW, Klokman WJ et al. Long-term causespecific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003; 21: 3431-3439.
17. Ng AK, Bernardo MV, Weller E et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002; 100: 1989-1996.
18. Brusamolino E, Anselmo AP, Klersy C et al. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher after combined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study. Haematologica 1998; 83: 812-823.
19. Franklin J, Pluetschow A, Paus M et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol 2006; 17: 1749-1760.
20. De Bruin ML, Sparidans J, van't Veer MB et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 2009; 27: 4239-4246.
21. Koh ES, Tran TH, Heydarian M et al. A comparison of mantle versus involvedfield radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol 2007; 2: 13.
22. Hodgson DC, Koh ES, Tran TH et al. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 2007; 110: 2576-2586.
23. van Leeuwen FE, Klokman WJ, Stovall M et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003; 95: 971-980.
24. Travis LB, Hill D, Dores GM et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005; 97: 1428-1437.
25. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993; 270: 1949-1955.
26. Filippi AR, Ciammella P, Namsyl-Kaletka A et al. Single institution preliminary experience on dose reduction to organs at risk in thoracic radiotherapy for patients enrolled in EORTC-GELA-IIL H10 study protocol on early stage Hodgkin's Lymphoma. Eur J Cancer Suppl 2009; 7: 158.
27. Paumier A, Ghalibafian M, Ferreira I et al. Involved-node radiotherapy (INRT) and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2011; 80(1): 199-205.
28. Tubiana M. Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review. Radiother Oncol 2009; 91: 4-15; discussion 11-13.